As part of the Government of India’s response to the COVID 19 Pandemic, the Department of Biotechnology (DBT), Ministry of Science and Technology, has been working with all stakeholders to address the urgent need of COVID 19 Vaccine. Biotechnology Industry Research Assistance Council (BIRAC) as a Government Enterprise has been identified by DBT to effectively implement Mission COVID Suraksha by setting up a Mission Implementation Unit (MIU).
COVID 19 pandemic is anticipated to lead to a loss of $2 trillion - $4.1 trillion -- 2.3% to 4.8% of the global gross domestic product. Recognizing its critical importance, rapid development and deployment of effective vaccines against COVID-19 is the need of the hour with ~66 candidates in clinical trials globally (data as per WHO compilation, accessed on 31st Oct’20).
Vaccine development is a lengthy, expensive process, typically taking an average of 10-15 years. But the current emergency does not provide this luxury of time. While the government efforts have helped quickly put together the best groups and encouraged them to accelerate the COVID vaccine development, it is now imperative that the COVID vaccine development and manufacture are taken up in a Mission mode and not in a project mode.
Therefore, to ensure a steady supply of vaccines in the next 12-18 months, DBT has established Mission COVID Suraksha. The focus of this mission is to consolidate and streamline available resources towards a warpath for accelerated vaccine development. This will be a National Mission working to bring to the citizens of the country a safe, efficacious, affordable, and accessible COVID vaccine at the earliest with a focus on Atma Nirbhar Bharat and fulfil our commitment of serving not just the country but the entire globe.
It must be ensured that all vaccines being introduced through the Mission have preferred characteristics applicable for India and that is proposed to be achieved by strengthening the following functional domains:
To enable the above, this Request for Expression of Interest (REOI) is to seek EOI/ application only for : Enhancing capacity for conduct of Human clinical trials for COVID-19 Vaccine candidates as per the instructions given below. Other published REOIs on Vaccine Development, Immunogenicity lab establishment and Animal challenge facilities may be accessed through BIRAC website.
Ensure availability and access to Good Clinical Practice (GCP) compliant clinical trial sites to vaccine developers. The trial sites will be both for supporting hospital-based sites for performing early stage clinical trials and large scale Phase III clinical trials through access to community based healthy population.
NOTE: Funding is not available for Contract Research Organizations or Site Management Organization
Announcement Date: 05-12-2020
Last Submission Date: 25-12-2020 05:00 PM